Rigel has crossed the rare biotech inflection point—profitable multi-product execution today, with asymmetric upside (and real competitive risk) riding on R289’s 2026 MDS data.
Overview
Rigel Pharmaceuticals (RIGL) is positioned as a profitable, commercial-stage biotech that has transitioned from a historically cash-burning R&D model into a multi-product revenue and cash-flow generator. As of early 2026, the company markets three targeted small-molecule therapies—TAVALISSE (ITP), REZLIDHIA (IDH1-mutant R/R AML), and GAVRETO (RET+ NSCLC/thyroid)—serving specialized hematology and oncology populations often relapsed/refractory to prior standards of care. Revenue comes from U.S. product sales plus collaboration/contract revenues via international partners (e.g., Kissei, Grifols, Medison, Dr. Reddy’s), enabling global monetization without building heavy ex-U.S. SG&A. FY2025 was a financial inflection: preliminary total revenue of ~$294.3M (vs. $179.3M in 2024) driven by ~$232.0M net product sales (+60% YoY) and $62.3M contract revenue, alongside disciplined costs that supported GAAP profitability and strong liquidity (~$154.6M cash/investments exiting 2025). With profitability and cash generation now funding pipeline advancement—especially R289 in lower-risk MDS—Rigel’s investment profile is reframed as a resilient commercial compounder with meaningful pipeline optionality rather than a purely speculative biotech.